Suicidality and Quality of Life in Treatment-Resistant Depression Patients in Latin America: Secondary Interim Analysis of the TRAL Study.

Background

A large proportion of patients with major depressive disorder (MDD) have treatment-resistant depression (TRD). The TRAL study examines the impact of TRD on suicidality and health-related quality of life (HRQoL) among MDD patients in 4 Latin American countries.

Methods

In this multicenter, prospective, observational study, MDD patients were recruited from 33 sites in Mexico, Colombia, Brazil, and Argentina. Patients were assessed for TRD, defined as failure to respond to ≥2 antidepressant medications of adequate dose and duration. Other assessments included current disease status, Mini International Neuropsychiatric Interview (MINI), Columbia-Suicide Severity Rating Scale (C-SSRS), 5 Level EQ-5D (EQ-5D-5L), Patient Health Questionnaire-9 (PHQ-9), and Sheehan Disability Scale (SDS).

Results

1,475 MDD patients were included in the analysis (mean age, 45.6 years; 78% women), and 429 met criteria for TRD. Thoughts of suicide and suicide attempts were more common among TRD patients (38.7%) compared with non-TRD patients (24.9%;

Conclusion

TRD patients in clinical sites from Mexico, Colombia, Brazil, and Argentina were more likely to experience suicidality and negative effects on HRQoL than non-TRD patients.

Informations de copyright

Copyright © 2022 Corral, Alessandria, Agudelo Baena, Ferro, Duque, Quarantini, Caldieraro, Cabrera and Kanevsky.

Déclaration de conflit d'intérêts

RC has received funding and honoraria from Janssen for research and serving in an advisory role and as a speaker. HA has received research funding from, and served as a speaker for, Janssen-Cilag. LMAB has received research funding from Janssen-Cilag, Lundbeck, Acadia, TEVA Pharmaceuticals, Otsuka, and Takeda. EF, XD, and MAC have received research funding from Janssen. LQ has received consulting fees from Allergan, Abbot, Cristalia, Janssen Pharmaceutical, and Lundbeck, and has received research funding from Fapex and Janssen Pharmaceutical. PC was an employee of Janssen-Cilag at the time of her work on this study and is currently affiliated with Janssen Global Services, Inc. GK is an employee of Janssen-Cilag. This study received funding from Janssen Pharmaceutical Companies of Johnson & Johnson. The funder had the following involvement with the study: study design, conduction, monitoring, database analysis, medical writing of the manuscript, and submission for publication.